Search results
Results From The WOW.Com Content Network
With a $999 price-tag, it’s leaps and bounds more expensive than the next highest-priced tier you can buy. The service starts at $999 for a full year, and renews at $499. The service starts at ...
23andMe published its most recent second-quarter financial results in November. The company said it earned $44 million in total revenue, a 12% decrease from the $50 million recorded in the same ...
23andMe's once rising star has dimmed amid a series of setbacks, leading some users to wonder what will happen to their genetic data. 23andMe is floundering. Here is how to delete your data.
Three-quarters of Lemonaid's $400 million acquisition was paid as shares of 23andMe stock. 23andMe was valued at $3.5 billion when it went public in 2021. On Friday it was valued at about $91 million.
The Food and Drug Administration decided that 23andMe’s test and health reports about a person’s predisposition to various diseases circumvented the regulator.
23andMe continued to evolve its services, and in 2015, the FDA granted authorization to market its screening for Bloom syndrome, a rare genetic disorder, the company said at the time.
Whether in search of relatives, a family's country of origin, or to understand personal disease risk, 15 million people have shared their DNA with 23andMe since the genetic test site launched in 2006.
23andMe posted another loss in quarterly earnings released Tuesday. The company reported a net loss of $59.1 million for the 2025 fiscal year's second quarter, compared to a loss of $75.3 million ...